Search clinical trials for: Farletuzumab ecteribulin

Total 15 results

Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Neoplasms, Ovarian

Australia, United States, Korea, Republic of, Chile, Belgium, Italy, Spain, Israel, Japan
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Carcinoma, Non-Small-Cell Lung

United States, Australia, Belgium, Chile, France, Spain
Eisai Inc.
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Solid Tumor

United States, Spain, United Kingdom, France
Eisai Inc.

Completed

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Solid Tumors

Japan
Dr. Frank Arguello Cancer Clinic
Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia...

Recruiting

Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

Neoplasms

Mexico
Morphotek
Eisai Europe Ltd. (United Kingdom)

Terminated

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Ovarian Cancer

United States, Hong Kong, Netherlands, Spain, Korea, Republic of, Belgium, Taiwan, Israel, Japan, France, United Kingdom, Singapore, Italy, Argentina, India, Germany, Hungary, Australia, Portugal, Russian Federation, Canada, Poland, Greec... and more
Morphotek

Terminated

An Open Label Extension Study of the Efficacy of MORAb-003

Epithelial Ovarian Cancer

United States, Germany
Eisai Inc.

Completed

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Platinum-Sensitive Ovarian Cancer in First Relapse

United States, Italy, United Kingdom, Germany, Spain, Belgium, Japan
Morphotek

Completed

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Adenocarcinoma of the Lung

Spain, United States, Australia, Canada, Germany, Italy, Poland, Russian Federation
Eisai Co., Ltd.

Completed

A Study of MORAb-003 in Patients With Solid Tumor

Neoplasms | Solid Tumor

Japan
Morphotek

Terminated

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer (FAR-122)

Ovarian Cancer

Canada, United States, Netherlands, Spain, Belgium, Australia
Morphotek

Completed

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Germany
Morphotek

Completed

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Epithelial Ovarian Cancer

United States
Morphotek

Completed

Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

Epithelial Ovarian Cancer

United States
Morphotek

Withdrawn

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Resectable, Non-functioning Pituitary Adenoma

United States

3

Subscribe